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Background: Patients with hematogenous metastatic lung cancer displayed significantly increased platelet count
and aggregation compared to lung cancer patients without hematogenous metastasis. The mechanism underlying
the correlation between the lung cancer hematogenous metastasis and platelet activation remains unknown.
Results: In the present study, we explored the role of microRNA-223 (miR-223) derived from platelets in modulating
lung cancer cell invasion. Our results demonstrated that platelets from NSCLC patients contain higher level of
miR-223 than that from healthy subjects. The concentration of miR-223 in the platelet-secreted microvesicles
(P-MVs) from NSCLC patients was also increased compared to that from healthy subjects. Incubation of human
lung cancer A549 cells with P-MVs resulted in rapid delivery of miR-223 into A549 cells, in which platelet miR-223
targeted EPB41L3 and thus promoted A549 cell invasion. The effect of P-MVs on reducing EPB41L3 in A549 cells
but promoting tumor cell invasion could be largely abolished by depletion of miR-223 via transfection with
miR-223 antagomir. The role of EPB41L3 in inhibiting A549 cell invasion was further validated by directly downregulating
EPB41L3 via transfecting cells with EPB41L3 siRNA or miR-223 mimic.
Conclusions: Our study demonstrates for the first time that platelet-secreted miR-223 via P-MVs can promote lung cancer
cell invasion via targeting tumor suppressor EPB41L3.
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Lung cancer is the most common cause of cancer-
related death in the world. Non-small cell lung cancer
(NSCLC) comprises approximately 80% of lung cancers
[1]. Hematogenous and lymphatic metastases are the
most common metastatic pathways for lung cancers. At
the earlier stages, lung cancer cell metastasizes through
the lymphatic system. As hematogenous metastasis often
occurs when lung cancer develops into an advanced
stage, hematogenous metastasis is generally associated
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It has previously demonstrated that, compared with
healthy controls and lung cancer patients without
hematogenous metastasis, patients with hematogenous
metastatic lung cancer displayed significantly in-
creased platelet count and aggregation [3]. Close cor-
relation between the hematogenous metastasis of lung
cancer and platelet activation was also reported by
others [4]. However, the mechanism underlying the
role of platelets in modulating the hematogenous me-
tastasis of lung cancer remains unclear.
It has been well documented that activated platelets
release large amount of microvesicles (MVs) [5,6]. Plate-
lets are major sources of MVs in peripheral bloodstream
as two-thirds of peripheral blood MVs is likely derived
from platelets [7]. In response to the stimuli of various
inflammatory factors or under many disease states suchhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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bosis [11], thrombotic thrombocytopenia [12], uremia
[13], malignancy [14] and rheumatoid arthritis [15],
platelets can release more MVs. Similar to MVs derived
from other cells, platelet MVs (P-MVs) bear platelet
surface receptors/ligands and have the potential to se-
lectively interact with specific target cells. Increasing
evidence demonstrates that P-MVs play a role in coagu-
lation, angiogenesis, the metastatic spread of lung cancer
[9], and the immune response of hematopoietic, endo-
thelial, and monocytic cells [16,17]. P-MVs have also
been implicated in the pathogenesis of atherosclerosis as
well as the regulation of angiogenesis [16,18]. These
findings suggest that, without the physical contact with
the target cells, platelets can affect the functional state
of the cells through releasing P-MVs. However, despite
the extensive studies regarding P-MVs in various physio-
logical and pathological processes, the mechanism that
governs the role of P-MVs in target cells, particularly
cancer cells, remains to be further explored.
MicroRNAs (miRNAs) are a class of noncoding RNAs
that post-transcriptionally regulate gene expression in
plants and animals [19]. Through guiding the binding of
the RNA-induced silencing complex (RISC) to comple-
mentary sequences in the 3-untranslated region (UTR)
or the open reading frame (ORF) of target mRNA mole-
cules, miRNAs either degrade mRNA or block the gene
translation. Accumulating evidence has demonstrated
that miRNAs play a key role in the cellular processes of
differentiation, proliferation, maturation, and apoptosis.
Our recent studies have demonstrated that miRNAs are
stably expressed in animal serum/plasma and that their
unique expression patterns serve as “fingerprints” of
various diseases [20]. Mechanistic studies further suggest
that cells can selectively secret miRNAs via MVs in re-
sponse to various stimuli and that these MV-encapsulated
miRNAs are associated with Argonaute 2 (AGO2) com-
plexes [21,22]. Secreted miRNAs in MVs can be efficiently
delivered into target cells, in which they silence their tar-
get genes and thus affect recipient cell function [21,23].
Therefore, cell-secreted miRNAs in MVs can serve as a
novel class of signaling molecules to remotely mediate
intercellular communication.
Recent studies have shown that anucleate platelets also
contain abundant miRNAs [24-27], though the biogen-
esis pathway of miRNAs in anucleate platelets remains
unclear. In addition, platelets have been shown to ex-
press certain miRNA processing machinery including
Dicer, RNA-binding protein 2 and AGO2 [24], implying
that platelet miRNA may have biological functions and
that platelets may be able to process pre-miRNA into
mature miRNA. Diehl et al. [28] reported that miRNAs,
including miR-19, miR-21, miR-126, miR-133, miR-146
and miR-223, could be detected in P-MVs, suggestingthat platelets can secrete their miRNAs through P-MVs.
Delivery of functional platelet miRNAs into endothelial
cells via P-MVs has be reported recently [29,30]. Al-
though many mRNAs have been predicted to be targets
of these platelet miRNAs, the function of platelet miR-
NAs particularly the miRNAs stored in P-MVs, has yet
to be shown. The work by Gidlof and co-workers [30]
provided the first evidence that activated platelets can
release functional miRNA, which can be taken up by
endothelial cells and regulate endothelial intercellular
adhesion molecules 1 (ICAM1) expression, suggesting
that delivery of functional platelet miRNAs into vascular
endothelial cells by P-MVs can play a critical role in
modulating vascular endothelial inflammatory responses.
Recently, we reported that P-MVs could effectively de-
liver miR-223 into human umbilical vein endothelial
cells (HUVECs), in which platelet miR-223 targeted IGF-
1R and promoted HUVEC apoptosis induced by ad-
vanced glycation end products (AGEs) [31]. Given that
miR-223 is the most abundant miRNA in the platelets
and P-MVs [31,32] and its expression is deregulated in
many types of cancer [33-36], it is considered as a mem-
ber of an emerging family of tumor-promoting miRNAs
called oncomiRs. It has been reported that miR-223
could promote breast cancer invasiveness by suppressing
Mef2c (Myocyte enhancer factor 2c) [33]. Li et al. [34]
examined miRNAs in several human gastric cell lines
and showed that miR-223 is specifically overexpressed in
metastatic gastric cells and stimulates tumor cell inva-
sion. It has been also reported that miR-223 directly tar-
get the 3′UTR of erythrocyte membrane protein band
4.1-like 3 (EPB41L3) [35] and is the most upregulated
miRNA in recurrent tumors [36].
In the present study, we explored the role of miR-223
derived from anucleate platelets in modulating lung can-
cer cell invasion. Our results demonstrated that platelets
from NSCLC patients contain higher level of miR-223
than that from healthy subjects. The concentration of
miR-223 in the P-MVs from NSCLC patients was also
increased compared to that from healthy subjects. Fur-
thermore, we showed that P-MVs could effectively de-
liver miR-223 into human lung cancer cells A549, in
which platelet miR-223 targeted EPB41L3 and thus pro-
moted A549 invasion.
Results
Levels of miR-223 and pre-miR-223 in platelets from
NSCLC patients were significantly increased compared to
that from healthy volunteers
The clinical parameters of platelets of 20 cases of diag-
nosed NSCLC patients and 20 cases of diagnosed
healthy donors were determined at the Jinling Hospital
(Nanjing, China) (Table 1). As the results of previous
studies [3,4], we found the platelet numbers (PLT) and
Table 1 Demography and clinical features of NSCLC patients and healthy subjects
Variable Normal volunters (N = 20) NSCLC patients (N = 20) p-value
NO. % NO. % (LC vs Health)
Average age (years) 60.6 ± 8.93 63.57 ± 10.26 0.535
Sex (male) 14 70 12 60 0.612
Smoking status current 9 45 10 50 0.798
Ever 2 10 3 15
Never 9 45 7 35
Histological type Adenocarinoma 6 30
Squamous cell carcinoma 10 50
Large cell carcinoma 4 20
Stage I/II 5 25
III 6 30
IV 9 45
Statistical comparison was performed by using Student’s t-test.
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nificantly higher than healthy donors, while the mean
platelet volume (MPV) and platelet distribution width
(PDW) were no different between NSCLC patients and
healthy donors. As miR-223 is the most abundant
miRNA in the platelets [25,31,37], we compared the
miR-223 level in the platelets from NSCLC patients with
that from healthy volunteers using TaqMan probe-based
qRT-PCR assay. As shown in Figure 1A, miR-223 in the
platelet of per milliliter blood from NSCLC patients in-
creased about 10-fold than healthy volunteers. We found
that the miR-223 level increased from 3.86 × 10−8 fM of
healthy volunteers to 1.80 × 10−6 fM of NSCLC patients
per platelet (Additional file 1: Figure S1). As anucleate
platelets have no nuclear microprocessor components
such as Drosha and DGCR8 [25], the de novo biogenesis
of miRNA should be not considered as a mechanism
underlying the upregulation of miRNAs in platelets.
However, Landry et al. [24] have shown that platelets
have Dicer and AGO2 and are capable of processing
pre-miRNAs into mature miRNAs. The up-regulation of
miRNAs in platelets of NSCLC patients may be due to
the enhanced maturation of pre-miRNAs. We thus
assayed the levels of pre-miR-223 in platelets. The cellu-
lar levels of pre-miR-223 were detected by qRT-PCR
using the primer listed in Additional file 1: Table S1. As
shown in Figure 1B, the levels of pre-miR-223 in the
platelets of NSCLC patients were rapidly increased com-
pared to platelets of healthy volunteers, which is in-
versely correlated to the up-regulation of miR-223 in
platelets of NSCLC patients. Taken together, these
results implicate that the levels of miR-223 and pre-
miR-223 in the platelets of NSCLC patients relatively in-
creased compared to healthy volunteers. By intravenous
injection, we successfully established a mouse model of
Lewis lung carcinoma in situ (Additional file 1: FigureS2) and also found that the concentration of miR-223
and pre-miR-223 in platelet from mouse peripheral
bloodstream was significantly elevated compared to nor-
mal mice (Figure 1C and D).
MiR-223 significantly increased in MVs derived from
platelets of NSCLC patients
It has been widely reported that activated platelets re-
lease large amount of microvesicles (P-MVs), especially
after stimulation with agonists including thrombin or ex-
posure to high-stress shear forces [13,31,38,39]. In fact,
previous studies suggest that the majority of MVs in per-
ipheral bloodstream are derived from platelets, while
mononuclear phagocytes are the second most abundant
population [40,41]. Numerous studies show that P-MVs
were substantially increased in tumor patients compared
to the healthy persons [21,42,43]. We measured the
levels of miR-223 in P-MVs and found that not only
P-MVs contained considerable levels of miR-223, but
also the levels of miR-223 in P-MVs was significantly in-
creased in NSCLC patients compared to healthy volun-
teers (Figure 2A). Interestingly, we also found that the
concentration of miR-223 in circulating MVs from
mouse peripheral bloodstream was significantly elevated
compared to normal mice (Figure 2B). Because P-MVs
generally account for two-thirds of circulating MVs in
peripheral bloodstream, this result suggests that P-MVs
from Lewis lung carcinoma mice contain a higher level
of miR-223 than normal mice.
P-MVs effectively deliver miR-223 into the recipient
A549 cells
Recently, the studies by us [31] and Laffont et al. [32]
have demonstrated that platelet secreted MVs can effect-
ively deliver miRNAs into the recipient cells to modulate
the expression of their target genes. To determine the
Figure 1 The levels of miR-223 and pre-miR-223 in platelets isolated from NSCLC patients or Lewis lung carcinoma mice. (A) The
absolute levels of miR-223 in the platelet from healthy volunteers and NSCLC patients detected by qRT-PCR. (B) The relative levels of pre-miR-223
in the platelet from healthy volunteers and NSCLC patients detected by qRT-PCR. (C) The absolute levels of miR-223 in the platelet of Lewis lung
carcinoma mice detected by qRT-PCR. (D) The relative levels of pre-miR-223 in the platelet of Lewis lung carcinoma mice detected by qRT-PCR.
The levels of miR-223 and pre-miR-223 were assessed by qRT-PCR and normalized against blood volume. Results are presented as mean ± SEM of
five independent experiments (*, P < 0.05, **, P < 0.01,***, P < 0.001).
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P-MVs, we studied the delivery of miR-223 into A549
cells via P-MVs. First, the comparison of miR-223 levels
in A549 cells, platelets of healthy volunteers and NSCLC
patients, and P-MVs by TaqMan probe-based qRT-PCR
assay clearly showed that miR-223 level in platelets
(Figure 3A) and P-MVs (Figure 3B) was much higher
than that in A549 cells, especially, the miR-223 level in
P-MVs of NSCLC patients is about 100-fold more thanA549 cells. Second, we collected P-MVs released from
platelets and incubated the P-MVs with cultured A549
cells, as depicted in Figure 3C. For tracing the P-MVs in
A549 cells, we labeled the P-MVs with DiI-C16 and
then detected the localization of fluorescent P-MVs in
A549 cells after incubation at different temperatures. As
shown in Figure 3D, fluorescent P-MVs were found rap-
idly entering the cultured A549 cells after incubation at
37°C (in red), whereas the internalization of P-MVs into
Figure 2 The level of miR-223 in P-MVs isolated from NSCLC patients and Lewis lung carcinoma mice. (A) The absolute levels of miRNAs
in the P-MVs isolated from healthy volunteers and NSCLC patients detected by qRT-PCR. (B) The absolute levels of miRNAs in the P-MVs isolated
from control mice and Lewis lung carcinoma mice detected by qRT-PCR. Results are presented as mean ± SEM of five independent experiments
(*, P < 0.05, **, P < 0.01, ***, P < 0.001).
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internalization of P-MVs into recipient cells is an active
process. In agreement with this observation, incubation
of A549 cells with P-MVs at 37°C strongly increased
miR-223 level, and this elevation could be largely abol-
ished by co-transfecting A549 cells with anti-miR-223
antisense oligonucleotide (ASO) (Figure 3E). In contrast,
the pre-miR-223 level in the recipient A549 cells was
not altered by incubation with P-MVs (Figure 3F), sug-
gesting that the elevation of miR-223 level in A549 cells
is not due to de novo miRNA biosynthesis but derived
from P-MV delivery. More interestingly, although the in-
cubation with P-MVs of healthy volunteers could in-
crease the miR-223 level in the A549 cells more than
20-fold, incubation with the P-MVs of NSCLC patients
further increased the miR-223 level in the A549 cells
more than 200-fold (Figure 3E).
Platelet miR-223 promotes A549 cells invasion via
targeting EPB41L3
To determine whether exogenous miR-223 delivered by
P-MVs has a biological function in A549 cells, we ana-
lyzed the potential target genes of miR-223 using three
computer-aided algorithms, TargetScan, miRanda, and
PicTar. As shown in Figure 4A, we predicted EPB41L3
as a target gene of miR-223. As the previous study [34],
overexpression of miR-223 in A549 cells via transfection
of miR-223 mimic (Figure 4B) clearly showed that miR-223 strongly reduced protein level (Figure 4D and E). As
expected, luciferase activity was also markedly reduced
in the cells transfected with pre-miR-223 (Figure 4C).
Furthermore, we introduced point mutations into the
corresponding complementary sites in the 3′-UTR of
EPB41L3 to eliminate the predicted miR-223 binding
sites. This mutated luciferase reporter was unaffected by
overexpression miR-223 (Figure 4C). This finding sug-
gested that the binding site strongly contribute to the
interaction between miR-223 and EPB41L3 mRNA.
Moreover, compared with cells transfected with pre-
miR-223 alone, those transfected with both pre-miR-223
and the EPB41L3-expressing plasmid lack of the miR-
223-responsive 3′-UTR, exhibited higher EPB41L3
protein levels (Figure 4F and G), suggesting that
miR-223-resistant EPB41L3 is sufficient to rescue the
suppression of EPB41L3 by miR-223. In conclusion, our
results demonstrated that miR-223 directly binds to the
3′-UTR of the EPB41L3 mRNA transcript and inhibits
EPB41L3 translation.
We next determined whether the exogenous miR-223
delivered by P-MVs could affect the level of EPB41L3 in
the recipient A549 cells. Western blot analysis demon-
strated that incubation of A549 cells with P-MVs signifi-
cantly decreased the levels of cellular EPB41L3 protein,
and this reduction of EPB41L3 protein levels by P-MVs
was largely abolished by co-transfection with the anti-
miR-223 ASO (Figure 5A and B). These results
Figure 3 Effective delivery of platelet miR-223 into A549 cells by P-MVs. (A) Comparison of the absolute levels of miR-223 in platelets and
A549 cells. The level of miR-223 was assessed by qRT-PCR and normalized against the amount of total RNA. (B) Comparison of the absolute levels
of miR-223 in P-MVs and A549 cells. The level of miR-223 was assessed by qRT-PCR and normalized against the amount of total RNA. (C) Flow
chart of the experimental design. (D) Confocal microscopy image of the internalization of fluorescently labeled MVs into A549 cells. Platelets were
labeled with DiI-C16 (red). After incubation for 4 h, the supernatants were collected and centrifuged to harvest P-MVs. The isolated P-MVs were
re-suspended in RPMI 1640 medium supplemented with 10% FBS and incubated with A549 cells at 4°C or 37°C, respectively. After incubation for
2 h, A549 cells were washed, fixed, and observed under confocal microscopy. (E-F) Quantitative RT-PCR analysis of miR-223 (E) and pre-miR-223
(F) expression level in A549 cells treated without P-MVs (mock) or with P-MVs from various sources for 24 h. Data are presented as the mean ±
SEM of five independent experiments (*, P < 0.05, **, P < 0.01,***, P < 0.001).
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ducing EPB41L3 levels in the A549 cells. More interest-
ingly, the P-MVs of NSCLC patients significantly
suppressed the EPB41L3 protein level in A549 cells
compared to P-MVs of healthy volunteers.EPB41L3, a member of the band 4.1 family of cytoskel-
etal proteins, is considered to function as a linker be-
tween the actin cytoskeleton and transmembrane
proteins [44]. EPB41L3 can regulate cell shape, cell–cell
and cell–substrate adhesion, cell motility, and take part
Figure 4 Direct regulation of EPB41L3 expression by miR-223. (A) Schematic depicting the hypothetical duplexes formed by the interactions
between the binding sites in the EPB41L3 3′-UTR (top) and miR-223 (bottom). The predicted free energy value of each hybrid is indicated. The
seed recognition sites are denoted, and all nucleotides in these regions are highly conserved across species, including human, mouse and rat.
(B) Quantitative RT-PCR analysis of miR-223 levels in A549 cells treated with pre-miR-control and pre-miR-223. (C) Firefly luciferase reporters containing
wild-type (WT) or mutant (MUT) miR-223 binding sites in the EPB41L3 3′-UTR were co-transfected into A549 cells along with pre-miR-control, or
pre-miR-223. he cells were assayed using a luciferase assay kit 24 h post-transfection. (D-E) Western blotting analysis of EPB41L3 protein levels in A549
cells treated with pre-miR-control, or pre-miR-223. D: representative image; E: quantitative analysis. (F-G)Western blotting analysis of EPB41L3 protein
levels in A549 cells treated with pre-miR-control plus control plasmid, pre-miR-control plus EPB41L3 plasmid, pre-miR-223 plus control
plasmid, or pre-miR-223 plus EPB41L3 plasmid. F: representative image; G: quantitative analysis. Data are presented as the mean ± SEM
of five independent experiments (*, P < 0.05, **, P < 0.01,***, P < 0.001).
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creased motility and increased adhesion due to EPB41L3
re/overexpression has been shown in several different
cancer cell lines [45,46]. Furthermore, siRNA knock-
down of EPB41L3 in non-metastatic cell lines stimulated
invasion and the loss of actin stress fibers [47]. As de-
tachment of tumor cells from the primary tumor and in-
vasion into the surrounding tissue is the first step of the
metastatic cascade [48], these functions of EPB41L3 in-
dicate a possible metastasis suppressor activity [49].
We determined the possible role of miR-223 delivered
by P-MVs targeting EPB41L3 in modulating the A549
cells invasion process. As the previous study [34], A549cells transfected with pre-miR-223 showed an increased
invasion (Figure 6A and B). Subsequently, we investi-
gated whether overexpression or knockdown of
EPB41L3 would have an impact on cell invasion. To
knock down EPB41L3, a siRNA targeting EPB41L3
was designed and then transfected into A549 cells. To
overexpress EPB41L3, an expression plasmid designed
to specifically express the full-length open reading frame
(ORF) of EPB41L3 without the miR-223-responsive 3′-
UTR was also constructed and transfected into A549 cells.
Efficient knockdown and overexpression of EPB41L3 in
A549 cells were shown in Additional file 1: Figure S3,
A-C. A549 cells transfected with EPB41L3 siRNA showed
Figure 5 Exogenous miR-223 delivered by P-MVs reduced EPB41L3 protein expression in A549 cells. (A-B) EPB41L3 protein levels of A549
cells treated without P-MVs (Mock), or with P-MVs from various sources for 24 h. A: representative image; B: quantitative analysis. Data are presented as
the mean ± SEM of five independent experiments (*, P < 0.05, **, P < 0.01,***, P < 0.001).
Figure 6 Platelet miR-223 delivered by P-MVs promotes A549 cells migration. (A-B) Invasion of A549 cells treated without P-MVs (mock) or
with P-MVs from various sources using Transwell assay. A: representative image; B: quantitative analysis. Data are presented as the mean ± SEM of
five independent experiments (*, P < 0.05, **, P < 0.01,***, P < 0.001).
Liang et al. Molecular Cancer  (2015) 14:58 Page 8 of 13
Liang et al. Molecular Cancer  (2015) 14:58 Page 9 of 13promote cell invasion; in contrast, transfection with the
EPB41L3-overexpression plasmid had the opposite effect
on cell invasion (Additional file 1: Figure S3, D-E). More-
over, compared with cells transfected with pre-miR-223
alone, those transfected with both pre-miR-223 and the
EPB41L3-overexpression plasmid exhibited significantly
lower invasion rates (Figure 6A and B), suggesting that
miR-223-resistant EPB41L3 sufficiently attenuated the
promotion effect of invasion of miR-223 on lung cancer
cells. While P-MVs could effectively deliver miR-223 into
the recipient A549 cells (Figure 3E), the invasion of A549
cells strongly increased when A549 cells incubated with P-
MVs, especially, the P-MVs of NSCLC patients promoted
the invasion about 100-fold compared to the P-MVs of
healthy volunteers (Figure 6A and B). The promotion of
A549 cells invasion by P-MVs was largely abolished by
depleting miR-223 using anti-miR-223 ASO and over-
expressing EPB41L3 via miR-223-resistant EPB41L3-
expressing plasmid (Figure 6A and B). These results
collectively showed that platelet-secreted miR-223 via
P-MVs could be effectively delivered into A549 cells,
in which it targets EPB41L3, and thus promotes cell
invasion.
Discussion
Thrombocytosis is frequently observed in patients with
solid tumors and is associated with adverse outcomes of
tumor patients. In agreement with this, we also found
that PLT and PCT in NSCLC patients were significantly
higher than those in cancer-free controls (Table 2). The
mechanism underlying the association between throm-
bocytosis and tumor progression, however, remains un-
clear. The contribution of platelets to the pathogenesis
of cancer is highly complex and dependent upon bidirec-
tional cross-talk between platelets, tumor cells, leuko-
cytes, stromal cells, and endothelial cells. Platelets exert
their influence on tumor cells through multiple mecha-
nisms, including direct cellular contact, local release of
soluble proteins, transfer of cytoplasmic and cell surface
proteins, modulation of vascular tone and permeability,
activation of coagulation, and sequestration of tumor cell
proteins. In addition to the physical interaction with dif-
ferent cells and the secretion of proteins, platelets can
release a large amount of functionally active MVs, which
enter the circulation, interact with other cells and affect
the function of the target cells. MVs are small vesicles
shed from almost all cell types under both normal andTable 2 Clinical parameters of platelets from healthy donors
Sample number PLT (×109/L)
Healthy 20 212.53 ± 45.41
NSCLC 20 268.47 ± 73.62***
PLT, platelets; PCT, Platelet hematocrit; MPV, Mean platelet volume; PDW, platelet d
t-test (*, P < 0.05, **, P < 0.01, ***, P < 0.001).pathological conditions [7]. Platelets are major sources
of MVs in peripheral bloodstream and two-thirds of per-
ipheral blood MVs is likely derived from platelets [50].
In response to the stimuli of various inflammatory fac-
tors or under many disease states such as sepsis [8,9],
thrombocytopenia [10], arterial thrombosis [11], throm-
botic thrombocytopenia [12], uremia [13], malignancy
[14] and rheumatoid arthritis [15], platelets release sig-
nificantly more MVs. Similar to MVs derived from other
cells, P-MVs bear platelet surface receptors/ligands and
have the potential to selectively interact with specific tar-
get cells. Increasing evidence demonstrates that P-MVs
play a role in coagulation, angiogenesis, the metastatic
spread of lung cancer [9], and the immune response of
hematopoietic, endothelial, and monocytic cells [16,17].
P-MVs have also been implicated in the pathogenesis of
atherosclerosis as well as the regulation of angiogenesiss
[16,18]. These findings suggest that platelets can affect
the functional state of other cells without the physical
contact through releasing P-MVs.
In the present study, we reported that P-MVs contain
various miRNAs, particularly miR-223, which displays
the highest level in platelets, and these platelet miRNAs
can be delivered into recipient tumor cells via P-MVs. In
the recipient cells, platelet miRNAs suppress the transla-
tion of their target genes through forming RISC complex
and thus change the phenotype of the cells. First, we
found that the levels of miR-223 in both platelets and
P-MVs were significantly upregulated in lung cancer pa-
tients compared to those in cancer-free controls. Second,
in vitro assays with cell tracing and qRT-PCR analysis
showed that platelet miR-223 was rapidly delivered into
lung cancer cells via P-MVs. Third, exogenous miR-223
derived from platelets reduced the protein level of tumor
suppressor EPB41L3 and thus promoted the lung cancer
cells invasion. The effect of P-MVs on EPB41L3 reduc-
tion and enhancement of tumor cell invasion was largely
abolished by depleting miR-223, suggesting that miR-223
play a key role in these processes. This study provides
another evidence supporting the concept that cell-
secreted MVs serve as physiological carriers of func-
tional miRNAs in exchanging genetic materials and sig-
naling molecules between cells [51,52].
As a hematopoietic-specific miRNA with crucial func-
tions in myeloid lineage development [53,54], miR-223
has been shown to target a transcription factor Mef2c
[53], CEBP-beta [55], glutamate receptors (GluR2 andand lung cancer patients
PCT (%) MPV (fl) PDW (%)
0.2095 ± 0.09 8.35 ± 1.35 14.9 ± 1.75
0.2694 ± 0.04** 9.65 ± 1.9 16.4 ± 1.50
istribution width; Statistical comparison was performed by using Student’s
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types. By the luciferase reporter assay and experimental
validation, we confirmed EPB41L3 as a target of miR-
223 in lung cancer A549 cells. To support the role of
miR-223-targeting EPB41L3 to promote A549 cells inva-
sion, direct silencing of EPB41L3 expression by EPB41L3
siRNA showed an increased A549 cells invasion and
overexpressing of EPB41L3 expression by miR-223-
resistant EPB41L3-overexpress plasmid showed a sup-
pressed A549 cell invasion (Additional file 1: Figure
S3). Although the effect of factors other than platelet
miR-223 on the reduction of EPB41L3 and promotion
of A549 cells invasion cannot be excluded at this
stage, depleting miR-223 in A549 cells by anti-miR-
223 ASO largely reversed the enhancement of A549
cell invasion by P-MVs, implicating that miR-223 in P-
MVs plays a key role in modulating A549 cell invasion
by P-MVs. The effect of P-MVs on reducing target cell
EPB41L3 and promoting tumor cell invasion is in pro-
portion to the level of miR-223 in P-MVs. As can be
seen in Figure 6, treatment with the P-MVs from
NSCLC patients, which contain higher level of miR-
223 than the P-MVs from cancer-free donors, resulted
in the largest invasion of tumor cells.
Recent studies by others [24-30] and us [31] have
shown that anucleate platelets contain large amount of
miRNAs and these platelet miRNAs are clinically and
biologically relevant. Interestingly, we found that, under
tumor condition, the level of miR-223 in both platelets
and P-MVs were increased. This is in agreement with
our previous finding that platelet miRNAs are upregu-
lated following platelet activation [31]. Although our
data indicate that upregulation of miR-223 in anucleate
platelets is not derived from de novo miR-223 synthetic
pathway but from the direct maturation of pre-miR-223,
the mechanism by which the upregulation of miRNAs in
platelets is governed remains to be further explored.
Conclusions
In summary, our results demonstrate the miR-223 level
in the platelet and P-MVs were significantly increased
during lung cancers patients, and that through release of
miR-223-containing P-MVs, platelets of lung cancers pa-
tients can remotely modulate the invasion of lung cancer
cells. Furthermore, as depletion of miR-223 by anti-miR-
223 ASO and miR-223-resistant EPB41L3-overexpress
plasmid treatment can effectively decreased A549 cells
invasion, our study also provides a potential miRNA-
based therapeutic strategy for lung cancers.
Materials and method
Reagents, cells and antibodies
Human lung cancer cells (A549 cells) and mouse lung
cancer cells (LLC cells) were purchased from the ChinaCell Culture Center (Shanghai, China) and cultured in
DMEM supplemented with 10% fetal bovine serum
(GIBCO, Foster City, CA), all cells were incubated in a
5% CO2 at 37°C in a water-saturated atmosphere. Anti-
EPB41L3 and anti-GAPDH antibodies were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA). Synthetic
oligonucleotides, including pre-miR-223, anti-miR-223, and
scrambled negative control (pre-miR-control and anti-miR-
control), were purchased from Ambion (Austin, TX).
Animals
Animal maintenance and experimental procedures were
carried out in accordance with the US National Institute
of Health Guidelines for Use of Experimental Animals
and approved by the Medicine Animal Care Committee
of Nanjing University (Nanjing, China). The logarithmic
phase of LLC cells were collected and injected into SCID
mice (the Model Animal Research Centre of Nanjing
University) (1 × 106 cell/per mouse) via the tail vein to
establish Lewis lung carcinoma orthotopic model
[58,59]. After mice were sacrificed at the end of the
experiment, blood samples were collected via cardiac
puncture and tumor section slides were subjected to
immunohistochemical analysis using H&E staining.
Blood collection
Patients with pathologically confirmed, newly diagnosed
and untreated cancers were recruited at the Jinling
Hospital (Nanjing, China). Blood samples were collected
from the patients and healthy participants at the Jinling
Hospital. Written informed consent was obtained from
each patient and healthy participant prior to the study,
and the study protocol was approved by the ethics com-
mittee of Nanjing University (Nanjing, China). The clin-
ical features of the patients are listed in Table 1.
Platelet isolation
Platelet-rich plasma was diluted in washing buffer
(10 mM HEPES, 136 mM NaCl, 2.7 mM KCl, 2 mM
MgCl2, 25 mM glucose, 4.2 mM EDTA, 4.2 mM triso-
dium citrate and 1 mM PGE, pH 6.6). The platelet
suspension was centrifuged at 750 g for 15 min at
20°C, and the pellet was re-suspended in wash buffer
without PGE for an additional centrifugation in the
same conditions. Finally, platelets were recovered in
suspension buffer (10 mM HEPES, 136 mM NaCl,
2.7 mM KCl, 2 mM MgCl2, 25 mM glucose).
Microvesicle isolation and incubation with A549 cells
To isolate P-MVs, platelets in PRP were centrifuged at
2000 g for 15 min at 4°C, and the PMP-enriched plasma
was collected. The plasma was centrifuged at 100,000 g
for 1 h at 4°C in a TL-100 ultracentrifuge (Beckman
Coulter). P-MVs were collected from the pellet and
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bation of P-MVs with A549 cells, A549 cells were seeded
on 12-well dishes the night before, and 200 μg P-MVs
isolated from platelets were added into each well. After
incubation for 24 h, A549 cells were collected for qRT-
PCR and the quantitative protein assay.
Fluorescence labeling of P-MVs for confocal microscopy
To analyze the P-MVs released from platelets under
various conditions, platelets were labeled with DiI-C16
and then washed three times with PBS. The cells were
re-suspended and the supernatant was collected and
centrifuged to isolate P-MVs. P-MVs in DMEM medium
were incubated with cultured A549 cells. After incuba-
tion for 12 h, A549 cells were washed, fixed, and ob-
served under confocal microscopy (FV1000; Olympus,
Tokyo). The pictures were taken under the following
conditions: Objective Lens: PLAPON 60× O NA: 1.42;
Scan Mode: XY; Excitation Wavelength: 405 nm for
DAPI and 543 nm for DiI-C16; Image Size: 1024 × 1024
Pixel.
RNA isolation and quantitative RT-PCR of miRNAs and
pre-miRNA
Total RNA was extracted using TRIzol Reagent (Invi-
trogen). Quantitative RT-PCR was carried out using
TaqMan miRNA probes (Applied Biosystems; Foster
City, CA) or synthesized primer (Invitrogen). Briefly,
5 μl of total RNA was reverse transcribed to cDNA
using AMV reverse transcriptase (TaKaRa; Dalian,
China) and a stem-loop RT primer (Applied Biosys-
tems). Real-time PCR was performed using a TaqMan
PCR kit on the 7300 Sequence Detection System (Applied
Biosystems). All reactions, including no-template controls,
were run in triplicate. After the reaction, the CT values
were determined using fixed threshold settings. To calcu-
late the absolute expression levels of target miRNAs, a
series of synthetic miRNA oligonucleotides at known con-
centrations were also reverse transcribed and amplified.
The absolute amount of each miRNA was then calculated
by referring to the standard curve. In the experiments pre-
sented here, miRNA expression in A549 cells is normal-
ized to U6. Because platelets are anucleate, miRNA
expression in platelet cells is normalized to the total RNA
sampling amount. The expression levels of target miRNAs
in platelet MVs were directly normalized to the total pro-
tein content of MVs.
Luciferase reporter assay
To test the direct binding of miR-223 to the target gene
EPB41L3, a luciferase reporter assay was performed. The
entire 3′-UTR of human EPB41L3 was PCR amplified
from human genomic DNA. The PCR products were
inserted into the p-MIR-reporter plasmid (Ambion) andthe insertion was confirmed by sequencing. To test the
binding specificity, the sequences that interacted with
the miR-223 seed sequence were mutated (from AACU-
GAC to UUGACUG), and the mutant EPB41L3 3′-UTR
was inserted into an equivalent luciferase reporter. For
luciferase reporter assays, A549 cells were cultured in
24-well plates, and each well was transfected with 1 μg
of firefly luciferase reporter plasmid, 1 μg of a β-
galactosidase (β-gal) expression plasmid (Ambion), and
equal amounts (100 pmol) of pre-miR-223 or the scram-
bled negative control RNA using Lipofectamine 2000
(Invitrogen). The β-gal plasmid was used as a transfec-
tion control. Cells were assayed using a luciferase assay
kit 24 h post-transfection (Promega, Madison, WI).
Transfection with pre-miR-control, pre-miR-223, small
interference RNAs (siRNAs) and miR-223-resistant
EPB41L3-expressing plasmid
A549 cells were seeded on 6-well dishes and were
transfected the following day using Lipofectamine 2000
(Invitrogen). For miR-223 overexpression, 100 pM pre-
miR-223 or scrambled control miRNA (pre-miR control)
was used (Invitrogen). Cells were harvested 24 h after
transfection. EPB41L3 siRNA was designed to target the
coding region of the EPB41L3 mRNA (5′-GCUC
GAAUAUCAGCAAUUA-3′). Negative control siRNAs
(siRNA control), which do not lead to the specific deg-
radation of any known cellular mRNA, were used as the
negative control. A mammalian expression plasmid en-
coding the human EPB41L3 open reading frame (pRe-
ceiver-M02-EPB41L3) was purchased from GeneCopoeia
(Germantown, MD). An empty plasmid served as a
negative control. The siRNAs and plasmid were deliv-
ered into the cultured A549 cells by Lipofectamine 2000
(Invitrogen). At 24 h post-transfection, RNAs were
extracted for qRT-PCR analyses and cell lysates were
prepared for western blot. Cell invasion assays were per-
formed at 24 h post-transfection.
Invasion assay
For transwell invasion assays, 1 × 105 cells were plated in
the top chamber with Matrigel-coated membrane (24-
well insert; 8-mm pore size; Corning Costar Corp). Cells
were plated in medium without serum. Medium supple-
mented with serum was used as a chemoattractant in
the lower chamber. The cells were incubated for 24 h
and cells that did not invade through the pores were re-
moved by a cotton swab. Cells on the lower surface of
the membranes were fixed with methanol and stained
with H&E.
Western blotting
EPB41L3 protein levels were quantified by western blot
analysis of whole-cell extracts using antibodies against
Liang et al. Molecular Cancer  (2015) 14:58 Page 12 of 13EPB41L3. Normalization was performed by blotting the
same samples with an antibody against GAPDH. Protein
bands were analyzed using Bandscan software (Image J).
Statistical analysis
All images of western blots and flow cytometry are rep-
resentative of at least three independent experiments.
For each experiment, qRT-PCR assays were performed
in triplicate. The data are presented as the means ± SEM
for three or more independent experiments. Differences
are considered statistically significant at p < 0.05, analyzed
using Student’s t-test.
Additional file
Additional file 1: Table S1. PCR Primers used to amplify the human
miRNAs precursors. Figure S1. The absolute levels of miRNAs in platelets
from cancer-free volunteers and NSCLC patients detected by qRT-PCR.
Results are presented as mean ± SEM of five independent experiments
(*, P < 0.05, **, P < 0.01,***, P < 0.001). Figure S2. Representative H&E-stained
sections of the lung tissues from the Lewis lung carcinoma mice. Figure S3.
Downregulation of EPB41L3 by siRNA and upregulation of EPB41L3 by an
overexpression vector in A549 cells. (A) Quantitative RT-PCR analysis of
EPB41L3 mRNA levels in A549 cells treated with control siRNA or EPB41L3
siRNA, control plasmid or EPB41L3 plasmid. (B and C) Western blotting
analysis of EPB41L3 protein levels in A549 cells treated with control siRNA or
EPB41L3 siRNA, control plasmid or EPB41L3 plasmid. B: representative image;
C: quantitative analysis. (D and E) Transwell analysis of A549 cells treated
with control siRNA or EPB41L3 siRNA, control plasmid or EPB41L3 plasmid
for 24 h. D: representative image; E: quantitative analysis. Data are presented
as the mean ± SEM of five independent experiments (*, P < 0.05, **,
P < 0.01,***, P < 0.001).
Abbreviations
EPB41L3: Band 4.1-like protein 3; miR-223: microRNA-223; NSCLC: Non-small
cell lung cancer; P-MVs: Platelet-secreted microvesicles; MVs: Microvesicles;
PLT: Platelet numbers; PCT: Platelet hematocrit; MPV: The mean platelet
volume; PDW: Platelet distribution width.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
KZ, HG and CYZ designed the research and analyzed data. KZ drafted the
manuscript. YP, HL, XY, YW, JZ, LL, and XC performed research and analyzed
data. All authors read and approved the final manuscript.
Acknowledgements
This work was supported by grants from the National Basic Research
Program of China (973 Program, 2012CB517603 and 2011CB504803), the
National Natural Science Foundation of China (No. 81401895, 30988003,
30225037, 30471991, 30570731) and the Natural Science Foundation of
Jiangsu Province (No. BK2011013).
Author details
1From State Key Laboratory of Pharmaceutical Biotechnology, Nanjing
University School of Life Sciences, Jiangsu Engineering Research Center for
MicroRNA Biology and Biotechnology, Nanjing, Jiangsu 210093, China. 2The
Comprehensive Cancer Center of Drum Tower Hospital affiliated to Medical
School of Nanjing University & Clinical Cancer Institute of Nanjing University,
Nanjing, Jiangsu 210008, China. 3Department of Respiratory Medicine,
Nanjing Drum Tower Hospital Affiliated to Medical School of Nanjing
University, 321 Zhongshan Road, Nanjing 210008, Jiangsu Province, China.
4Department of Biology, Georgia State University, Atlanta, GA 30303, USA.Received: 28 September 2014 Accepted: 25 February 2015References
1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin.
2013;63:11–30.
2. Inamura K, Ishikawa Y. Lung cancer progression and metastasis from the
prognostic point of view. Clin Exp Metastasis. 2010;27:389–97.
3. Kunita A, Kashima TG, Morishita Y, Fukayama M, Kato Y, Tsuruo T. The
platelet aggregation-inducing factor aggrus/podoplanin promotes
pulmonary metastasis. Am J Pathol. 2007;170:1337–47.
4. Gonzalez Barcala FJ, Garcia Prim JM, Moldes Rodriguez M, Alvarez
Fernandez J, Rey Rey MJ, Pose Reino A, et al. Platelet count: association
with prognosis in lung cancer. Med Oncol. 2010;27:357–62.
5. Escola JM, Kleijmeer MJ, Stoorvogel W, Griffith JM, Yoshie O, Geuze HJ.
Selective enrichment of tetraspan proteins on the internal vesicles of
multivesicular endosomes and on exosomes secreted by human
B-lymphocytes. J Biol Chem. 1998;273:20121–7.
6. Miyamoto S, Kowalska MA, Marcinkiewicz C, Marcinkiewicz MM, Mosser D,
Edmunds Jr LH, et al. Interaction of leukocytes with platelet microparticles
derived from outdated platelet concentrates. Thromb Haemost.
1998;80:982–8.
7. Thery C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and
function. Nat Rev Immunol. 2002;2:569–79.
8. Janiszewski M, Do Carmo AO, Pedro MA, Silva E, Knobel E, Laurindo FR.
Platelet-derived exosomes of septic individuals possess proapoptotic NAD
(P)H oxidase activity: A novel vascular redox pathway. Crit Care Med.
2004;32:818–25.
9. Janowska-Wieczorek A, Wysoczynski M, Kijowski J, Marquez-Curtis L,
Machalinski B, Ratajczak J, et al. Microvesicles derived from activated
platelets induce metastasis and angiogenesis in lung cancer. Int J Cancer.
2005;113:752–60.
10. Hughes M, Hayward CP, Warkentin TE, Horsewood P, Chorneyko KA, Kelton
JG. Morphological analysis of microparticle generation in heparin-induced
thrombocytopenia. Blood. 2000;96:188–94.
11. Mallat Z, Benamer H, Hugel B, Benessiano J, Steg PG, Freyssinet JM, et al.
Elevated levels of shed membrane microparticles with procoagulant
potential in the peripheral circulating blood of patients with acute coronary
syndromes. Circulation. 2000;101:841–3.
12. Galli M, Grassi A, Barbui T. Platelet-derived microvesicles in thrombotic
thrombocytopenic purpura and hemolytic uremic syndrome. Thromb
Haemost. 1996;75:427–31.
13. Ando M, Iwata A, Ozeki Y, Tsuchiya K, Akiba T, Nihei H. Circulating platelet-
derived microparticles with procoagulant activity may be a potential cause
of thrombosis in uremic patients. Kidney Int. 2002;62:1757–63.
14. Varon D, Shai E. Role of platelet-derived microparticles in angiogenesis and
tumor progression. Discov Med. 2009;8:237–41.
15. Boilard E, Nigrovic PA, Larabee K, Watts GF, Coblyn JS, Weinblatt ME, et al.
Platelets amplify inflammation in arthritis via collagen-dependent microparticle
production. Science. 2010;327:580–3.
16. Setzer F, Oberle V, Blass M, Moller E, Russwurm S, Deigner HP, et al. Platelet-
derived microvesicles induce differential gene expression in monocytic cells:
a DNA microarray study. Platelets. 2006;17:571–6.
17. Majka M, Kijowski J, Lesko E, Gozdizk J, Zupanska B, Ratajczak MZ. Evidence
that platelet-derived microvesicles may transfer platelet-specific immunoreactive
antigens to the surface of endothelial cells and CD34+ hematopoietic stem/
progenitor cells–implication for the pathogenesis of immune thrombocytopenias.
Folia Histochem Cytobiol. 2007;45:27–32.
18. Tan KT, Lip GY. The potential role of platelet microparticles in
atherosclerosis. Thromb Haemost. 2005;94:488–92.
19. Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism, and function
(Reprinted from Cell, vol 116, pg 281–297, 2004). Cell. 2007;131:11–29.
20. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of
microRNAs in serum: a novel class of biomarkers for diagnosis of cancer
and other diseases. Cell Res. 2008;18:997–1006.
21. Zhang Y, Liu D, Chen X, Li J, Li L, Bian Z, et al. Secreted monocytic miR-150
enhances targeted endothelial cell migration. Mol Cell. 2010;39:133–44.
22. Li L, Zhu D, Huang L, Zhang J, Bian Z, Chen X, et al. Argonaute 2 complexes
selectively protect the circulating microRNAs in cell-secreted microvesicles.
PLoS One. 2012;7:e46957.
Liang et al. Molecular Cancer  (2015) 14:58 Page 13 of 1323. Chen X, Liang H, Zhang J, Zen K, Zhang CY. Secreted microRNAs: a new
form of intercellular communication. Trends Cell Biol. 2012;22:125–32.
24. Landry P, Plante I, Ouellet DL, Perron MP, Rousseau G, Provost P. Existence
of a microRNA pathway in anucleate platelets. Nat Struct Mol Biol.
2009;16:961–6.
25. Nagalla S, Shaw C, Kong X, Kondkar AA, Edelstein LC, Ma L, et al. Platelet
microRNA-mRNA coexpression profiles correlate with platelet reactivity.
Blood. 2011;117:5189–97.
26. Kannan M, Mohan KV, Kulkarni S, Atreya C. Membrane array-based
differential profiling of platelets during storage for 52 miRNAs associated
with apoptosis. Transfusion. 2009;49:1443–50.
27. Kondkar AA, Bray MS, Leal SM, Nagalla S, Liu DJ, Jin Y, et al. VAMP8/
endobrevin is overexpressed in hyperreactive human platelets: suggested
role for platelet microRNA. J Thromb Haemost. 2010;8:369–78.
28. Diehl P, Fricke A, Sander L, Stamm J, Bassler N, Htun N, et al. Microparticles:
major transport vehicles for distinct microRNAs in circulation. Cardiovasc
Res. 2012;93:633–44.
29. Laffont B, Corduan A, Ple H, Duchez AC, Cloutier N, Boilard E, et al.
Activated platelets can deliver mRNA regulatory Ago2 microRNA complexes
to endothelial cells via microparticles. Blood. 2013;122(2):253–61.
30. Gidlof O, van der Brug M, Ohman J, Gilje P, Olde B, Wahlestedt C, et al.
Platelets activated during myocardial infarction release functional miRNA,
which can be taken up by endothelial cells and regulate ICAM1 expression.
Blood. 2013;121:3908–17.
31. Pan Y, Liang H, Liu H, Li D, Chen X, Li L, et al. Platelet-secreted microRNA-223
promotes endothelial cell apoptosis induced by advanced glycation end
products via targeting the insulin-like growth factor 1 receptor. J Immunol.
2014;192:437–46.
32. Laffont B, Corduan A, Ple H, Duchez AC, Cloutier N, Boilard E, et al.
Activated platelets can deliver mRNA regulatory Ago2.microRNA complexes
to endothelial cells via microparticles. Blood. 2013;122:253–61.
33. Yang M, Chen J, Su F, Yu B, Lin L, Liu Y, et al. Microvesicles secreted by
macrophages shuttle invasion-potentiating microRNAs into breast cancer
cells. Mol Cancer. 2011;10:117.
34. Li X, Zhang Y, Zhang H, Liu X, Gong T, Li M, et al. miRNA-223 promotes
gastric cancer invasion and metastasis by targeting tumor suppressor
EPB41L3. Mol Cancer Res. 2011;9:824–33.
35. Tran YK, Bogler O, Gorse KM, Wieland I, Green MR, Newsham IF. A novel
member of the NF2/ERM/4.1 superfamily with growth suppressing
properties in lung cancer. Cancer Res. 1999;59:35–43.
36. Laios A, O’Toole S, Flavin R, Martin C, Kelly L, Ring M, et al. Potential role of
miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer. 2008;7:35.
37. Hitzler W, Vamvakas EC. Platelet microRNA profiles and the effect of
pathogen reduction on platelet function. Clin Lab. 2011;57:451–4.
38. Alexandru N, Popov D, Georgescu A. Platelet dysfunction in vascular
pathologies and how can it be treated. Thromb Res. 2012;129:116–26.
39. Combes V, Simon AC, Grau GE, Arnoux D, Camoin L, Sabatier F, et al. In
vitro generation of endothelial microparticles and possible prothrombotic
activity in patients with lupus anticoagulant. J Clin Invest. 1999;104:93–102.
40. Ismail A, AlDorry A, Shaker M, Elwekeel R, Mokbel K, Zakaria D, et al.
Simultaneous injection of autologous mononuclear cells with TACE in HCC
patients; preliminary study. J Gastrointest Cancer. 2011;42:11–9.
41. Tantawy AA, Adly AA, Ismail EA, Habeeb NM. Flow cytometric assessment of
circulating platelet and erythrocytes microparticles in young thalassemia
major patients: relation to pulmonary hypertension and aortic wall stiffness.
Eur J Haematol. 2013;90:508–18.
42. Janowska-Wieczorek A, Marquez-Curtis LA, Wysoczynski M, Ratajczak MZ.
Enhancing effect of platelet-derived microvesicles on the invasive potential
of breast cancer cells. Transfusion. 2006;46:1199–209.
43. Bastida E, Ordinas A. Platelet contribution to the formation of metastatic
foci: the role of cancer cell-induced platelet activation. Haemostasis.
1988;18:29–36.
44. Gimm JA, An X, Nunomura W, Mohandas N. Functional characterization of
spectrin-actin-binding domains in 4.1 family of proteins. Biochemistry.
2002;41:7275–82.
45. Gutmann DH, Hirbe AC, Huang ZY, Haipek CA. The protein 4.1 tumor
suppressor, DAL-1, impairs cell motility, but regulates proliferation in a
cell-type-specific fashion. Neurobiol Dis. 2001;8:266–78.
46. Charboneau AL, Singh V, Yu T, Newsham IF. Suppression of growth and
increased cellular attachment after expression of DAL-1 in MCF-7 breast
cancer cells. Int J Cancer. 2002;100:181–8.47. Cavanna T, Pokorna E, Vesely P, Gray C, Zicha D. Evidence for protein 4.1B
acting as a metastasis suppressor. J Cell Sci. 2007;120:606–16.
48. Surace EI, Lusis E, Murakami Y, Scheithauer BW, Perry A, Gutmann DH. Loss
of tumor suppressor in lung cancer-1 (TSLC1) expression in meningioma
correlates with increased malignancy grade and reduced patient survival.
J Neuropathol Exp Neurol. 2004;63:1015–27.
49. Shabalina SA, Spiridonov NA. The mammalian transcriptome and the
function of non-coding DNA sequences. Genome Biol. 2004;5:105.
50. Hunter MP, Ismail N, Zhang X, Aguda BD, Lee EJ, Yu L, et al. Detection of
microRNA expression in human peripheral blood microvesicles. PLoS One.
2008;3:e3694.
51. Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M,
et al. Glioblastoma microvesicles transport RNA and proteins that promote
tumour growth and provide diagnostic biomarkers. Nat Cell Biol.
2008;10:1470–6.
52. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated
transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange
between cells. Nat Cell Biol. 2007;9:654–9.
53. Johnnidis JB, Harris MH, Wheeler RT, Stehling-Sun S, Lam MH, Kirak O, et al.
Regulation of progenitor cell proliferation and granulocyte function by
microRNA-223. Nature. 2008;451:1125–9.
54. Sun W, Shen W, Yang S, Hu F, Li H, Zhu TH. miR-223 and miR-142 attenuate
hematopoietic cell proliferation, and miR-223 positively regulates miR-142
through LMO2 isoforms and CEBP-beta. Cell Res. 2010;20:1158–69.
55. Chen X, Gao C, Li H, Huang L, Sun Q, Dong Y, et al. Identification and
characterization of microRNAs in raw milk during different periods of
lactation, commercial fluid, and powdered milk products. Cell Res.
2010;20:1128–37.
56. Harraz MM, Eacker SM, Wang X, Dawson TM, Dawson VL. MicroRNA-223 is
neuroprotective by targeting glutamate receptors. Proc Natl Acad Sci U S A.
2012;109:18962–7.
57. Jia CY, Li HH, Zhu XC, Dong YW, Fu D, Zhao QL, et al. MiR-223 suppresses
cell proliferation by targeting IGF-1R. PLoS One. 2011;6:e27008.
58. Palumbo JS, Kombrinck KW, Drew AF, Grimes TS, Kiser JH, Degen JL, et al.
Fibrinogen is an important determinant of the metastatic potential of
circulating tumor cells. Blood. 2000;96:3302–9.
59. Fabbri M, Paone A, Calore F, Galli R, Gaudio E, Santhanam R, et al.
MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory
response. Proc Natl Acad Sci U S A. 2012;109:E2110–6.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
